# Tirzepatide vs Semaglutide: 2026 PH Guide · PH Peptides

Source: https://www.philippinespeptides.com/guides/tirzepatide-vs-semaglutide
Updated: 2026-11-03

> Tirzepatide (Mounjaro/Zepbound) vs semaglutide (Ozempic/Wegovy) for PH buyers: head-to-head verdict on efficacy, side effects, and availability.

On this page

- [Quick Verdict](#verdict)

- [What Each One Is](#molecules)

- [Efficacy Data](#efficacy)

- [Side-by-Side](#comparison)

- [Side Effects](#tolerability)

- [PH Availability](#availability)

- [FAQ](#faq)

- [Related guides](#related)

# Tirzepatide vs Semaglutide: Mounjaro vs Ozempic, head-to-head

Philippines Peptides editorial desk Updated 3 November 2026 5 min read

**Stack**

- Dual vs Single

**Trial**

- SURMOUNT-5

Tirzepatide and semaglutide side by side

|  | Tirzepatide | Semaglutide |
| --- | --- | --- |
| Mechanism | Dual agonist: GLP-1 and GIP | Single agonist: GLP-1 only |
| Approval status | FDA approved 2022 (Mounjaro), 2023 (Zepbound) | FDA approved 2017 (Ozempic, diabetes), 2021 (Wegovy, obesity) |
| Side-effect profile | Thyroid cancer (in animal studies), pancreatitis and gallbladder warnings; nausea, constipation and fatigue during titration | Thyroid cancer (in animal studies), pancreatitis and gallbladder warnings; nausea, constipation and fatigue during titration |

**SURMOUNT-5: tirzepatidePhase 3b, 72 wk, head to head**

- 20.2%

**SURMOUNT-5: semaglutidePhase 3b, 72 wk, head to head**

- 13.7%

**Mechanism**

- GLP-1+GIP / GLP-1

Sourcing note: research-grade tirzepatide is research material, not a substitute for a prescribed Mounjaro pen. Primara Labs, our partner and supplier, holds research vials inside the Philippines; vials are batch-numbered, and Metro Manila orders verified before noon go out the same day. [Order tirzepatide 15mg](https://www.primaralabs.com/marketplace/tirzepatide-15mg?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=inline&utm_content=tirzepatide-vs-semaglutide)

## Quick verdict

In SURMOUNT-5, a 72-week phase 3b trial of 751 adults with obesity but without type 2 diabetes, mean body weight fell by 20.2% on tirzepatide, maximum tolerated dose, against 13.7% on semaglutide, maximum tolerated dose. [Source](https://doi.org/10.1056/NEJMoa2416394)

Semaglutide has the longer track record: Ozempic was approved by the US FDA in 2017, tirzepatide as Mounjaro in 2022. Which medicine suits a given person, and at what dose, is a decision for a licensed Philippine physician.

## What each one actually is

**Semaglutide** is a single-agonist GLP-1 drug developed by Novo Nordisk. It mimics the GLP-1 hormone your gut releases after eating. FDA approved 2017 (Ozempic, diabetes), 2021 (Wegovy, obesity).

**Tirzepatide** is a dual-agonist drug targeting GLP-1 AND GIP, developed by Eli Lilly. GIP is involved in fat storage, insulin response, and energy balance. In the one head-to-head trial, SURMOUNT-5, it produced more weight loss than semaglutide (figures below). FDA approved 2022 (Mounjaro), 2023 (Zepbound).

## Efficacy data

**STEP 1 (semaglutide):** In STEP 1, a 68-week phase 3 trial of 1,961 adults with BMI of 30 or greater (27 or greater with at least one weight-related coexisting condition), without diabetes, body weight fell by 14.9% on the 2.4 mg arm, against 2.4% on placebo. [Source](https://doi.org/10.1056/NEJMoa2032183)

**SURMOUNT-1 (tirzepatide):** In SURMOUNT-1, a 72-week phase 3 trial of 2,539 adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes, body weight fell by 15%, 19.5% and 20.9% on the 5 mg, 10 mg and 15 mg arms, against 3.1% on placebo. [Source](https://doi.org/10.1056/NEJMoa2206038)

**SURMOUNT-5 (head-to-head):** In SURMOUNT-5, a 72-week phase 3b trial of 751 adults with obesity but without type 2 diabetes, mean body weight fell by 20.2% on tirzepatide, maximum tolerated dose, against 13.7% on semaglutide, maximum tolerated dose. [Source](https://doi.org/10.1056/NEJMoa2416394)

## Side-by-side

| Metric | Semaglutide | Tirzepatide |
| --- | --- | --- |
| Mean weight loss, pivotal trial | 14.9% on 2.4 mg (STEP 1, phase 3, 68 wk) | 20.9% on 15 mg (SURMOUNT-1, phase 3, 72 wk) |
| Mechanism | GLP-1 only | GLP-1 + GIP |
| FDA approval | 2017 / 2021 | 2022 / 2023 |

## Side effects and tolerability

Both drugs share the same serious risk warnings: thyroid cancer (in animal studies), pancreatitis, and gallbladder issues. Both can cause nausea, constipation, and fatigue. In STEP 5, a 104-week phase 3 trial of 304 adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes, semaglutide reported nausea: 53.3% on the 2.4 mg arm, against 21.7% on placebo. In SURMOUNT-3, a 72-week phase 3 trial of 579 adults with BMI of 30 or more, or 27 or more with at least one obesity-related complication (excluding diabetes), who achieved 5.0% or more weight reduction after a 12-week intensive lifestyle intervention, tirzepatide reported nausea: 39.7% on the Maximum tolerated dose (10 or 15 mg) arm, against 14% on placebo. The two trials enrolled different populations, so the rates are not a direct comparison. See the [GLP-1 side effects guide](https://www.philippinespeptides.com/guides/glp1-side-effects) for management.

## Philippines availability reality

| Channel | Semaglutide | Tirzepatide |
| --- | --- | --- |
| FDA Philippines | Registered (Ozempic, Wegovy) | Registered (Mounjaro) |
| Prices | On the GLP-1 price tracker | On the GLP-1 price tracker |

Dated Philippine pharmacy prices are on the [semaglutide guide](https://www.philippinespeptides.com/peptides/semaglutide) (Ozempic) and the [Mounjaro page](https://www.philippinespeptides.com/guides/mounjaro-philippines).

Prescription only; prescribing belongs with a licensed Philippine physician. Trials and side effects: the [tirzepatide guide](https://www.philippinespeptides.com/peptides/tirzepatide). The law: [regulation hub](https://www.philippinespeptides.com/legal).

## Frequently asked questions

Which is better for weight loss, tirzepatide or semaglutide?

The one head-to-head trial favoured tirzepatide. In SURMOUNT-5, a 72-week phase 3b trial of 751 adults with obesity but without type 2 diabetes, mean body weight fell by 20.2% on tirzepatide, maximum tolerated dose, against 13.7% on semaglutide, maximum tolerated dose. Which medicine suits a given person is a decision for a licensed physician.

Is Mounjaro or Ozempic available in the Philippines?

Both are registered with FDA Philippines as prescription medicines: Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide). The pen prices Philippine pharmacies publish are dated on the GLP-1 price tracker, and Mercury Drug publishes none online. Prescribing belongs with a licensed Philippine physician.

Which has worse side effects?

No trial in the data this page draws on compares their side-effect rates head to head. Both carry the same label warnings (thyroid C-cell tumours in rodent studies, pancreatitis, gallbladder disease), and nausea is the most commonly reported effect of both. In STEP 5, a 104-week phase 3 trial of 304 adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes, semaglutide reported nausea: 53.3% on the 2.4 mg arm, against 21.7% on placebo. In SURMOUNT-3, a 72-week phase 3 trial of 579 adults with BMI of 30 or more, or 27 or more with at least one obesity-related complication (excluding diabetes), who achieved 5.0% or more weight reduction after a 12-week intensive lifestyle intervention, tirzepatide reported nausea: 39.7% on the Maximum tolerated dose (10 or 15 mg) arm, against 14% on placebo. The two trials enrolled different populations, so the rates are not a direct comparison.

How does research-grade tirzepatide differ from Mounjaro?

Mounjaro is a registered prescription medicine made and labelled to pharmaceutical standards. Research-grade tirzepatide is research material, not a pharmacy product, and it is not a substitute for a prescribed medicine. Prescribing belongs with a licensed Philippine physician.

Our partner and supplier

### Ready to order tirzepatide?

Primara Labs, our partner and supplier, holds stock inside the Philippines. Vials are batch-numbered, delivery is same day for Metro Manila orders placed before 12 noon and 1 to 5 business days elsewhere, and every order gets 10% off. These are research vials, not a substitute for a prescribed Mounjaro pen.

## Related guides

### Tirzepatide field reference

Mechanism, trials and side effects in full.

### Retatrutide vs tirzepatide

The triple agonist against the dual, on the same axes.

### Tirzepatide for weight loss

What the SURMOUNT trials found and the side effects they reported.

---
Philippines Peptides sells nothing. Primara Labs is our partner and supplier. This is general information, not medical or legal advice.